



MERCK

virtual symposium

How mRNA technology impacts our future

October 5th 2021

16.00–18.30 CET/10.00–12.00 EST



The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.

mRNA Virtual Symposium

The pandemic and the unprecedented success of mRNA-based COVID-19 vaccines have drawn attention and interest on mRNA technology, making it one of the most attractive technologies today.

Join our virtual mRNA Symposium to discover how mRNA technology will impact our future.

In this technical symposium chaired by Dr. Tanja Henzler, Director Liquid Formulation R&D at Merck KGaA, Darmstadt, Germany, industry experts will be presenting about various aspects of mRNA technology and latest trends.

- Learn about the potential of mRNA technology
- Get perspectives for a robust mRNA manufacturing process and efficient drug delivery
- Learn about regulatory aspects of mRNA
- Discuss and tackle today's mRNA challenges with your peers

The event is free of charge, though registration is required

*Agenda is subject to changes. Full agenda and panelists to follow. Attendance to the mRNA Symposium is limited and available to pharma/biopharma manufacturers only. The offer does not extend to any company that provides products or services to the pharma/biopharma industry. Merck reserves the right to revoke or refuse participation at any time.

Merck, the Vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

08/2021

Lit. No. MK_FL8363EN

Chair:

Dr. Tanja Henzler,

Director Liquid Formulation R&D
at Merck KGaA, Darmstadt, Germany

Speakers and presentations*:

1. Best Practices for efficient mRNA manufacturing

Nargisse El Hajjami,

Ph.D. Eng. Merck KGaA, Darmstadt, Germany

2. Stabilizing RNA nanocarriers by spray-drying for enhanced storage stability and inhalation delivery

Prof. Dr. Olivia Merkel,

LMU München

3. Regulatory considerations for mRNA

Dr. Ulrich Reichert,

Merck KGaA, Darmstadt, Germany

4. Enabling mRNA therapeutics: Lipids and LNP to drive the next paradigm in pharmaceuticals

Dr. Chris J. Barbosa,

Ph.D., Director of Technology Development
at Acuitas Therapeutics

[Learn More & Register Today >>](#)